Peptide Comparison
ARA-290 (Cibinetide)vsBPC-157
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
ARA-290 (Cibinetide)
0.16 mg–0.8 mg mg
BPC-157
250–500 mcg
Frequency
ARA-290 (Cibinetide)
Once daily
BPC-157
Once daily
Administration
ARA-290 (Cibinetide)
Subcutaneous injection
BPC-157
Subcutaneous injection
Cycle Length
ARA-290 (Cibinetide)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
ARA-290 (Cibinetide)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
ARA-290 (Cibinetide)
Moderate human trials (Phase 1-2)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Nerve Regeneration
Pain Management
Tissue Protection
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
ARA-290 (Cibinetide)
Molecular Formula
C51H84N16O21
Molecular Weight
1257.31 g/mol
Half-Life
Approximately 1-2 hours in circulation, but cellular effects last much longer
Bioavailability
Subcutaneous: ~100% (complete absorption); Intravenous: Immediate
CAS Number
1208243-50-8
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
ARA-290 (Cibinetide)
BPC-157
Applications
Best
suited for
ARA-290 (Cibinetide)
Treating small fiber neuropathy
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing neuropathic pain from diabetes or sarcoidosis
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting nerve regeneration after injury
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic inflammation
ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
ARA-290 (Cibinetide)
Common
- Injection Site Reactions
- Headache
- Dizziness
Uncommon
- Elevated Blood Pressure
- Fatigue
Serious
- Blood Clot Formation
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
ARA-290 (Cibinetide)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Not FDA approved
Safety Overview
ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.
Contraindications
- xPolycythemia vera or erythrocytosis
- xUncontrolled hypertension
- xPregnancy or breastfeeding
- xKnown hypersensitivity to peptides
- xConcurrent use with certain cancer medications
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose ARA-290 (Cibinetide) if...
- Treating small fiber neuropathy
- Managing neuropathic pain from diabetes or sarcoidosis
- Supporting nerve regeneration after injury
- Reducing chronic inflammation
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health